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Abstract
Background: Growth differentiation factor-15 (GDF-15), a stress-responsive transforming growth factor-ß-related 
cytokine, is elevated and independently related to an adverse prognosis in systolic heart failure.
Objective: This study aimed to investigate plasma levels of GDF-15 in patients with preclinical diastolic dysfunction or 
heart failure with normal ejection fraction (HFnEF).
Methods: We evaluated 119 patients with normal ejection fraction referred for an elective coronary angiography, 75 
(63%) of whom had coronary artery disease. Subjects were classified as having either mild left ventricular diastolic 
dysfunction (LVDD grade I, n = 61), HFnEF (LVDD grade II or III, n = 38) or normal diastolic function (controls, n = 20). 
In a subgroup of 20 subjects, changes in cardiac output (CO) were measured by inert gas rebreathing (InnocorTM) in 
response to an orthostatic hemodynamic test.
Results: Growth differentiation factor-15 levels in HFnEF [median 1.08, interquartile range (0.88-1.30) ng/ml] were 
significantly higher than in controls [0.60 (0.50-0.71) ng/ml, p = 0.003] and in patients with LVDD grade I [0.78 (0.62-
1.04) ng/ml, p < 0.001]. In addition, GDF-15 was significantly elevated in patients with LVDD grade I compared to 
controls (p = 0.003). Furthermore, GDF-15 was correlated with echocardiographic markers of diastolic dysfunction and 
was correlated with the magnitude of CO response to the change in body position from standing to supine (r = -0.67, 
p = 0.005).
Conclusion: Growth differentiation factor-15 levels are elevated in subjects with HFnEF and can differentiate normal 
diastolic function from asymptomatic LVDD. In addition, GDF-15 is associated with a reduced cardiac output response 
in the orthostatic hemodynamic test. (Arq Bras Cardiol. 2011; [online].ahead print, PP.0-0)
Keywords: Growth differentiation factor 15; heart failure; stroke volume; ventricular dysfunction.
Introduction
Nearly half of the patients presenting with symptoms and 
signs of heart failure have a normal ejection fraction (EF)1,2, a 
condition termed “heart failure with normal ejection fraction 
(HFnEF)”. Recent data suggest that overall mortality due to 
HFnEF is equivalent to that of systolic heart failure (SHF)1,2. In 
the general population, asymptomatic left ventricular diastolic 
dysfunction (LVDD), which is considered as a precursor of 
HFnEF3, is a powerful and independent predictor of death4. 
Nevertheless, clinical trials in HFnEF have been frequently 
disappointing, including those with drugs approved for 
SHF5-7. Notwithstanding the same overall mortality, this is 
at least in part due to the lower proportion of heart failure-
related death in the overall population of patients with 
HFnEF8. The discrepancies in mortality rates from heart 
failure-related deaths may be attributed to the considerable 
heterogeneity among patients with HFnEF, which can be 
explained by the use of different recruitment criteria9 or 
the complexity of echocardiographic diagnosis. Even though 
a specific guideline has been proposed recently by the 
American Society of Cardiology10, establishing this medical 
condition is difficult in clinical practice. Echocardiography 
can be misleading or inconclusive and will not always be 
sufficient to establish the diagnosis. Better characterization of 
patients with HFnEF at greatest risk for heart failure-related 
complications and death could allow more effective use of 
specific interventions. 
Biomarkers reflect distinct disease mechanisms, including 
neurohumoral activation, inflammation, myocyte injury and 
extracellular matrix turnover.
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Growth differentiation factor 15 (GDF-15) is a member of the 
transforming growth factor ß (TGF-ß) cytokine super-family and 
was first cloned as macrophage-inhibitory cytokine-111. Previous 
studies have shown that patients with SHF have increased 
circulating levels of GDF-1512, and it has been demonstrated 
that GDF-15 provides prognostic information beyond that 
established by clinical and biochemical risk factors13,14.
The aim of the present study was to test the diagnostic 
value of GDF-15 in identifying patients with preclinical, 
asymptomatic LVDD or HFnEF. Moreover, we analyzed the 
association of GDF-15 levels to different preload conditions. 
Methods
One hundred-nineteen consecutive subjects referred 
to elective coronary angiography for stable or suspected 
coronary artery disease (CAD) or diagnostic workup of heart 
failure were enrolled in the study. Patients that needed 
coronary revascularization with either angioplasty or coronary 
bypass surgery were not enrolled in the study. The protocol 
was approved by the local Ethics Committee, and signed 
informed consent was obtained from all patients. Exclusion 
criteria were left ventricular EF < 50%, known CAD with 
progressive chest pain within the last month, coronary 
angioplasty or myocardial infarction < 6 weeks, hypertrophic 
cardiomyopathy, moderate-to-severe valvular heart disease, 
uncontrolled hypertension, atrial fibrillation or other severe 
arrhythmias, or serum-creatinine > 2,0 mg/dl. In patients 
without diabetes, a standardized oral glucose tolerance test 
(oGTT) was performed (75 g glucose) according to the World 
Health Organization protocol as previously described15. Body 
mass index (BMI) was calculated as weight (kg)/height (m²). 
Echocardiography
Echocardiography was performed using a standard 
ultrasound system (Vivid 7, General Electric, Milwaukee, 
Wisconsin). Left ventricular EF was measured based on the 
modified biplane Simpson’s method. The left atrium volume 
index16 was calculated using the biplane area-length method16. 
Dimensions were recorded by standard techniques according 
to current guidelines17. Left ventricular mass index (LVMi) was 
calculated by the Devereux formula indexed to the body 
surface area17. Conventional transmitral flow was measured 
with pw-Doppler. Early (E), late atrial (A) transmitral peak 
flow velocities and the ratio (E/A) were measured and three 
consecutive beats were averaged. Pulsed wave tissue Doppler 
imaging (TDI) was performed at the junction of the septal 
and lateral mitral annulus and three consecutive beats were 
averaged. Early diastolic velocities (E’ medial, E’ lateral) were 
recorded; the mean value (E’ average) of E’ at the medial 
and lateral mitral annulus was determined. Ratios of E/E’ 
medial, E/E’ lateral and average E/E’ ratio were calculated. 
Diastolic dysfunction was classified according to the common 
consensus study by the American and European Society of 
Echocardiography (ASE, ESC)10. 
Inert gas-rebreathing (Innocor™)
A spirometry (Innocor™ device INNO0500) was performed 
to exclude relevant pulmonary dysfunction. Cardiac output 
(CO) was measured using an inert gas rebreathing (IGR) device 
(Innocor™, Innovision A/S, Denmark) in a subgroup with 
either normal diastolic function or asymptomatic mild LVDD 
(LVDD grade I, n = 10) and patients with HFnEF (LVDD grade 
II or III, n = 10). The method has been described in details 
elsewhere18 and has been validated in heart failure patients 
at rest and exertion19,20. For the IGR method, O2-enriched 
test gas with 0.5% N2O (blood soluble gas) and 0.1% SF6 
(blood insoluble gas) was used. The gas volume was adjusted 
to meet the physiological demand during rest. Use of SF6 
enabled the measurement of the volume of lungs, valve and 
rebreathing bag. The test gas concentration was decreased 
during the rebreathing maneuver, with a rate proportional to 
pulmonary blood flow (PBF). The slope of the N20 washout 
kinetics correlates with PBF and CO in the absence of 
pulmonary shunt. 
Prior to the measurements, patients were instructed on the 
rebreathing technique. The interval for measurements was a 
minimum of 3 minutes to allow complete inert gas clearance. 
CO was measured in different body positions as a model of 
ventricular load change and indexed for body surface area 
(BSA, COi). After 5 minutes of rest in supine position, CO 
was measured 3 times, and then body position was changed 
from supine to upright. After a three-minute period prior to 
the minimum period necessary to achieve a hemodynamic 
equilibrium, three consecutive measurements were performed. 
The measurements were averaged in each position.
Laboratory analysis
Blood samples were drawn at rest for the analysis of 
routine laboratory parameters and were stored at -80°C 
for later analysis. After thawing, GDF-15 was measured in 
plasma with a pre-commercial electrochemiluminescence 
immunoassay and NT-proBNP with a commercially available 
electrochemiluminescence immunoassay on an automated 
Elecsys™ analyzer (all Roche Diagnostics GmbH, Mannheim, 
Germany) by an investigator blinded to patient characteristics. 
Statistical analysis
All analyses were performed using SPSS statistical software 
(SPSS 17.0, Chicago, IL). The data are presented as medians 
(interquartile range) for continuous variables or absolute 
numbers (%) for categorical variables, unless otherwise 
specified. Log-transformed values were used for analysis as 
appropriate. A p value < 0.05 was considered statistically 
significant. Non-parametric tests for group differences between 
categories were performed. We used the Kruskal-Wallis test 
to test the equality of medians among more than two distinct 
groups. The Wilcoxon-Mann-Whitney U-test was used to 
analyze differences between the medians of two groups and 
the χ2 test to evaluate differences in proportions in more than 
2 sets of categorical variables. Fisher´s Test was used for the 
comparison of two sets of binary variables.
Growth differentiation factor-15 levels were compared 
across different grades of LVDD and different categories of the 
E/e’ average ratios and the LAi by the Jonckheere-Terpstra test. 
We used the Spearman rank correlation to identify variables 
associated with GDF15. Multivariate analysis of covariance 
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and logistic regression models, including most predictive 
variable for the dependent variables were built. Multiple linear 
regression analysis was applied to identify factors that were 
independently associated with GDF-15 levels. 
Results
Patient characteristics
We included 119 patients with normal EF (66 years [59-73]) 
in the study (45% woman), 63% of whom had CAD without 
the need for revascularization. Subjects were classified as 
having either mild LVDD (grade I, n = 61), HFnEF (LVDD 
grade II or III, n = 38) or normal diastolic function (normal DF, 
n = 20). Patients with HFnEF were older, had a higher mean 
NYHA functional class, higher systolic and mean arterial blood 
pressure values, a lower resting heart rate and were more likely 
to have diabetes compared to the group with normal DF (all p 
< 0.005). An oGTT was performed in 80 individuals, of whom 
35 (29%) had a normal glucose tolerance (NGT), 31 (26%) had 
impaired glucose tolerance (IGT) and 24 (20%) had newly 
detected diabetes. Twenty-nine patients had a history of type 
2 diabetes mellitus before inclusion in the study; therefore, 
53 (45%) individuals included in the study were identified as 
having type 2 diabetes mellitus (T2DM).Metabolic syndrome 
(MetS) was diagnosed in 51% of patients according to the 
amended National Cholesterol Education Program’s Adult 
Treatment Panel III (ATP-III)21. The clinical characteristics in 
patients classified as to the presence or absence of LVDD 
or HFnEF are shown in Table 1, the laboratory data and 
parameters of cardiac assessment are highlighted in Table 2. 
GDF-15 and diastolic function
In the whole study group, GDF-15 was significantly elevated 
in HFnEF patients (1.08 [0.88-1.30]) compared to those with 
normal diastolic function (0.60 [0.50-0.71], p < 0.001) or 
mild LVDD (0.78 [0.62-1.04], p < 0.001). In addition, GDF-
15 plasma levels were higher in subjects with mild LVDD 
compared to patients with normal diastolic function (p=0.003, 
Figure 1). When excluding subjects with CAD, GDF-15 
levels remained significantly associated with the severity of 
diastolic dysfunction (p < 0.001). The GDF-15 levels were 
closely related to the New York Heart Association (NYHA) 
functional class. In a multivariate lineal regression model 
including variables known to be associated with the presence 
of LVDD, age (ß = 0.456, p < 0.001) and the presence of mild 
LVDD or HFnEF (ß = 0.315, p = 0.001) were identified as 
variables predictive of higher GDF-15 levels. Female gender, 
the presence or absence of CAD, BMI, a history of T2DM, a 
previous myocardial infarction, left ventricular muscle mass 
and hypertension did not add significantly to the model 
(adjusted r2 = 0.39, p < 0.001 for overall model). 
The relationship between GDF-15 quartiles and clinical 
echocardiographic characteristics and NT-pro-BNP levels is 
shown in Table 3. Increasing quartiles of GDF-15 levels were 
associated with a higher EF, a higher LAi, a higher E/E’ septal 
and E/E’ average ratio and a lower E’ septal, lateral and average 
E’ ratio. In addition, GDF-15 quartiles were associated with 
higher NT-pro-BNP levels. Particularly among the association 
with echocardiographic parameters of diastolic dysfunction, 
GDF-15 levels were significantly increased across the LAi and 
the average E/E’ ratio, with both being indicative of elevated 
left atrial filling pressures (Figure 2a and Figure 2b). There 
was a weak linear correlation between the LAi (r = 0.354, p 
< 0.001) and the average E/E’ ratio with GDF-15 levels (r = 
0.613, p < 0.001).
In contrast, the global longitudinal strain values, a 
very sensitive tool to detect subtle systolic dysfunction 
disregarding a normal EF, were not associated with GDF 15 
levels. In addition, parameters of left ventricular geometry 
(left ventricular mass index, relative wall thickness and left 
ventricular end diastolic volume index) were not related to 
GDF-15 concentrations (Table 3). 
GDF15 and hemodynamic orthostatic test
In a substudy, COi was measured with inert gas- rebreathing 
technique, in supine and upright body positions, as a model 
of ventricular load change. In subjects with HFnEF, COi was 
1.96 [1.8-2.23] l/m2 in the upright position vs 1.90 [1.6-
1.93] l/min in subjects with normal DF or mild LVDD. After 
changes in body position from upright to supine, the HFnEF 
group increased COi by 7% [3-16%], whereas the non HFnEF 
group increased COi by 28% [23-16%], p = 0.002 (Figure 
3a). The COi response plotted against GDF-15 quartiles is 
shown in Figure 3b. GDF-15 was negatively correlated with 
the magnitude of COi response (r = -0.67, p = 0.005). 
Discussion
Growth differentiation factor-15 plasma levels are 
associated with the diagnosis of HFnEF and LVDD. 
Furthermore, GDF-15 levels are increased with more severe 
grades of LVDD and can differentiate subjects with normal 
DF and asymptomatic LVDD. Growth factor differentiation 
factor-15 levels correlates with the echocardiographic criteria 
implemented in the current guidelines for the diagnosis 
and classification of LVDD. This is the first study to show 
an association between GDF-15 levels and cardiac output 
response to different preload conditions serving as a functional 
parameter of hemodynamic reserve.
Experimental studies have shown that GDF-15 expression 
significantly increases in the heart after various forms of stress, 
including pressure overload22,23. Animal studies have shown 
that GDF-15 promotes protective, antiapoptotic and anti-
hypertrophic effects in the heart23. Considering the fact that 
GDF-15 is produced by several other cell types in addition to 
cardiomyocytes (endothelial cells, adipocytes, macrophages, 
vascular smooth muscle cells), it is likely that this biomarker 
integrates information from different disease pathways, 
providing a pathophysiological insight in patients with HFnEF.
The human GDF-15 promoter contains two p53 and two 
Egr1 consensus binding sites24. Increased expression of p53 has 
been detected in the failing human myocardium, and it has 
been suggested that it plays a role in the transition from cardiac 
hypertrophy to systolic heart failure25. Erg1 is induced in 
human atherosclerotic plaques26 and is a mediator of pressure 
overload hypertrophy in a mice model27. Therefore, GDF-15 
appears to have cardioprotective functions; those in SHF 
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Table 1 - Clinical characteristics
Normal DF mild LVDD HFnEF p-valuea all
Clinical variables
Age (years) 51 (48-58) 67 (60-72) 73 (66-77) <0.001* 66 (59-73)
Female gender, n (%) 7 (35) 27 (44) 20 (53) 0.426 54 (45)
BMI (kg/m2) 26 (24-30) 28 (25-31) 27 (25-32) 0.2 27 (25-32)
Waist circumference (cm) 98 (88-110) 107 (96-117) 104 (100-111) 0.96 104 (97-115)
Hip circumference (cm) 98 (91-105) 109 (96-114) 105 (99-114) 0.176 104 (95-114)
Systolic BP (mmHg) 123(110-130) 130(124-140) 133(130-140) 0.002* 130(120-140)
Diastolic BP (mmHg) 77(70-80) 80(72-86) 80(70-88) 0.111 80(70-86)
MAP (mmHg) 94 (83-96) 96 (92-101) 99 (93-103) 0.015* 96 (90-102)
Pulse pressure 42 (40-50) 52 (48-60) 50 (46-70) 0.016* 50 (41-60)
Resting HR (beats/min) 73 (68-80) 74 (65-80) 69 (65-77) 0.047* 72 (65-78)
CAD, n (%) 10 (50) 40 (65) 25 (66) 0.417 75 (63)
History of MI, n (%) 5 (25) 11 (18) 12 (32) 0.299 28 (23)
History of stroke, n (%) 0 2 (3) 3 (8) 0.339 5 (4)
History of PTCA, n (%) 9 (45) 28 (46) 19 (50) 0.905 56 (47)
Mean NYHA-class 1 (0.5-2) 2 (1-2) 2.5 (2-3) <0.001* 2 (1-2)
Cardiovascular risk factors
Treated hypertension 14 (70) 55 (92) 37 (98) 0.004* 106 (90)
Smoking, n (%) 8 (44) 8 (13) 7 (19) 0.013* 23 (20)
Family history of CAD 7 (35) 40 (66) 16 (43) 0.019* 63 (53)
Hyperlipidemia, n (%) 8 (40) 44 (72) 26 (68) 0.029* 78 (66)
Glucose metabolism status
NGT, n (%) 12 (60) 15 (25) 8 (21)
0.013*
35 (29)
IGT, n (%) 5 (25) 17 (28) 9 (24) 31 (26)
New detected T2DM, n (%) 2 (10) 10 (16) 12 (32) 24 (20)
Known T2DM, n (%) 1 (5) 19 (31) 9 (24) 29 (24)
Duration of T2DM (years) 2.5 (2-3) 5.5 (2-10) 14 (4-24.5) 0.076 5.5 (2.5-12.5)
Medications
ACE inhibitor, n (%) 12 (60) 37 (61) 23 (61) 0.999 72 (61)
AT1 receptor blocker, n (%) 0 11 (18) 12 (32) 0.014* 23 (20)
Diuretics, n (%) 1 (%) 18 (30) 21 (55) <0.001* 40 (34)
Ca2+ blocker, n (%) 3 (15) 8 (13) 13 (34) 0.032* 24 (20)
ß-Blocker, n (%) 11 (55%) 41 (67) 34 (89) 0.009* 86 (72)
Insulin therapy, n (%) 0 7 (14) 5 (16) 0.355 12 (13)
OAD, n (%) 1 (8) 12 (25) 3 (9) 0.109 16 (17)
Statin, n(%) 7 (35) 38 (62) 25 (65) 0.274 70 (59)
Acetyl salicylic acid, n (%) 10 (47) 51 (83) 29 (76%) 0.021* 90 76)
Values are median (interquartile range) or n (%). aMann-Whitney-Test, Jonckheere-Terpstra test, Fisher or χ2- test were used as appropriate, * statistically significant (p 
< 0.05). BMI - Body mass index, BP - blood pressure, CAD - Coronary Artery Disease, CABG - coronary bypass graft, DF - diastolic function, HFnEF - heart failure with 
normal ejection fraction, IGT - impaired glucose tolerance, LVDD - left ventricular diastolic dysfunction, NGT - normal glucose tolerance, HR - heart rate, MAP - mean arterial 
pressure, OAD - oral anti-diabetic therapy, PTCA - percutaneous coronary angioplasty, T2DM - type 2 diabetes mellitus.
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Table 2 - Laboratory data and Parameter of cardiac assessment according to diastolic function
Normal DF Mild LVDD HFnEF p-valuea
Biomarker
GDF-15 0.60 (0.50-0.71) 0.78 (0.62-1.04) 1.08 (0.88-1.30) <0.001*
NT-pro-BNP 98.5 (56.5-129.0) 96.0 (58.5-178.5) 525.5 (349.0-1.147.0) <0.001*
Routine parameter
Total cholesterol (mg/dl) 182 (165-199) 195 (172-225) 198 (164-210) 0.483
LDL-cholesterol (mg/dl) 103 (86-125) 111 (92-135) 110 (93-137) 0.495
HDL-cholesterol (mg/dl) 51 (42-60) 53 (40-62) 46 (40-56) 0.201
Triglyceride (mg/dl) 133 (111-186) 146 (98-206) 161 (119-212) 0.120
Lp (a) (mg/dl) 7 (5-21) 15 (5-35) 14 (6-58) 0.180
TSH (mU/l) 1.3 (0.9-2.3) 1.4 (0.9-2.1) 1.3 (0.9-1.8) 0.784
Creatinine (mg/dl) 0.8 (0.7-0.9) 0.9 (0.7-0.9) 0.9 (0.8-1.1) 0.003*
hsCRP 0.2 (0.1-0.5) 0.3 (0.1-0.6) 0.3(0.2-0.7) 0.248
HOMA-IR 1.14 (0.7-1.3) 1.6 (1.1-2.7) 1.8 (1.1-3.4) 0.019*
2h-PG (mg/dl) 126 (106-162) 142 (112-191) 170 (130-215) 0.016*
Hba1c (%) 5.7 (5.5-6.0) 6.1 (5.7-6.8) 6.2 (5.8-6.6) 0.015*
Systolic function
Ejection fraction (%) 64 (61-69) 65 (61-70) 70 (63-74) 0.028*
Smax (cm/s) 6.25 (5.65-6.75) 5.90 (5.05-7.15) 6.00 (5.30-6.80) 0.640
GLS ( -,%) 20.3 (21.6-18.2) 19.4 (21.8-16.6) 18.4 (21.2-16.4) 0.205
LV geometry
LVEDD (mm) 45 (43-48) 42 (39-47) 45 (42-51) 0.418
LVMi (g/m²) 79 (63-93) 81 (69-107) 104 (80-135) 0.003*
RWT 0.45 (0.40-0.48) 0.51 (0.46-0.67) 0.55 (0.44-0.63) 0.016*
Diastolic function
LA- Index (ml/m²) 25 (23-28) 29 (27-31) 42 (37-51) <0.001*
E (cm/s) 60 (60-75) 60 (50-70) 80 (70-100) 0.001*
A (cm/s) 60 (50-70) 80 (70-90) 80 (70-90) 0.014*
E/A ratio 1.2 (0.9-1.4) 0.8 (0.7-0.9) 1.1 (0.9-1.3) 0.148
E' septal (cm/s) 8.4 (7.6-9.3) 5.8 (5.1-6.7) 5.6 (4.4-6.2) 0.001*
E' lateral (cm/s) 11.1 (10.4-13.0) 7.9 (7.0-9.0) 7.0 (5.4-8.2) 0.001*
Average E' 9.7 (9.1-11.0) 7.1 (6.0-7.9) 6.3 (5.2-7.3) 0.001*
E/E' septal ratio 7.9 (7.2-8.6) 10.4 (8.5-12.2) 15.0 (12.3-17.2) 0.001*
E/E' average ratio 6.7 (5.9-7.4) 8.8 (7.4-10.3) 13.2 (10.9-15.4) 0.001*
* Statistically significant (p < 0.05). Jonckheere-Terpstra test. A - late diastolic transmitral inflow velocity, EF - ejection fraction. Smax - systolic velocity, DF - diastolic 
function, GPS - global longitudinal strain, LA - left atrial, E - early diastolic transmitral inflow velocity, E´septal - early diastolic tissue Doppler velocity septal, E´ lateral - early 
diastolic tissue Doppler velocity lateral, HFnEF - heart failure with normal ejection fraction, HOMA-IR - Homeostasis Model Assessment of Insulin Resistance, hsCRP - high 
sensitive c-reactive protein, LVEDD - left ventricular end-diastolic diameter, Lp (a) - Lipoprotein (a), LV - left ventricular, LVMi - left ventricular muscle mass index, NT-pro 
BNP - amino-terminal pro-B-type natriuretic peptide, PG - postprandial glucose, RWT - relative wall thickness, Smax - systolic velocity.
and higher levels are associated with adverse cardiovascular 
outcomes. Accordingly, higher levels of GDF-15 in patients 
with more advanced stages of LVDD (HFnEF, LVDD grad II or 
III) may reflect an adaptive response that is outweighed by the 
severity of the underlying disease. As GDF-15 predicts cardiac 
mortality in patients with CAD28, acute myocardial infarction29 
or SHF13, GDF-15 might be a future biomarker in patients with 
HFnEF, probably indicating prognosis. 
According to the current guidelines, patients can be 
classified as having HFnEF or LVDD without the need for 
objective evidence of hemodynamic limitation in exercise 
tolerance as a result of increasing preload or afterload 
conditions. Incoherent in the current diagnostic approach is 
that leading symptoms of patients with HFnEF are related to 
physical activity30, whereas ventricular performance obtained 
at rest does not accurately reflect exercise tolerance and 
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Figure 1 - Growth differentiation factor-15 levels in patients with normal diastolic function, mild diastolic dysfunction and heart failure with normal ejection fraction. GDF-15 
levels are presented as box (25th percentile, median, 75th percentile), and whiskers plots and upper outliers are presented as black dots. DF - diastolic function, GDF-15 
- growth differentiation factor-15, LVDD - left ventricular diastolic dysfunction.









Figure 2a - Growth differentiation factor-15 levels stratified according to left atrial volume index quartiles. Growth differentiation factor 15 (GDF-15) levels are presented 
as box (25th percentile, median, 75th percentile), and whiskers plots and upper outliers are presented as black dots. GDF-15 - growth differentiation factor 15. The left 
atrial volume index in the first quartile ranged from 19.3 - 26,7 ml/m2 body surface area (BSA), in the second quartile from 26,7 - 30,2 ml/m2, in the third quartile from 
30,2 - 37,5 ml/m2 and in the fourth quartile from 37,2 - 82,0 ml/m2 (p < 0.001 in the Jonckheere-Terpstra-Test).











GDF-15 in diastolic heart failure
Figure 2b - Growth differentiation factor-15 levels plotted against the E/E´ average ratio. GDF-15 levels are presented as box (25th percentile, median, 75th percentile), 
and whiskers plots and upper outliers are presented as black dots (p < 0.001for trend by Jonckheere-Tepstra). GDF-15 - growth differentiation factor-15.









E/E’ average 9-13 E/E’ average > 13
Table 3 - Parameters of cardiac assessment according to GDF-15 levels
GDF-15 1rd quartile GDF-15 2nd quartile GDF-15 3rd quartile GDF-15 4th quartile p- valuea
Systolic function
Ejection fraction (%) 65 (62-70) 63 (59-68) 65 (61-72) 70 (64-73) 0.021*
Smax (cm/s) 6.60 (5.70-7.15) 5.90 (5.30-7.00) 5.65 (5.00-6.50) 6.10 (5.10-6.90) 0.283
GLS (-,%) 19.0 (21.3-16.9) 18.9 (21.4-16.6) 18.9 (20.5-17.5) 19.0 (22.0-17.1) 0.956
LV geometry
LVEDD (mm) 43 (41-47) 45 (41-49) 44 (39-50) 44 (41-48) 0.851
LVMi (g/m²) 79 (64-96) 96 (72-108) 83.1 (71-127) 92 (67-117) 0.326
RWT 0.50 (0.40-0.60) 0.49 (0.44-0.62) 0.54 (0.45-0.63) 0.51 (0.45-0.69) 0.145
Diastolic function
LA- Index (ml/m²) 27 (25-30) 29 (24-34) 34 (28-40) 36 (30-46) <0.001*
E (cm/s) 60 (60-70) 70 (60-70) 60 (50-70) 70 (60-90) 0.047*
A (cm/s) 70 (60-80) 80 (70-90) 80 (70-90) 80 (65-95) 0.129
E/A ratio 0.9 (0.8-0.9) 0.9 (0.8-1.0) 0.8 (0.7-1.2) 0.9 (0.7-1.2) 0.978
E' septal (cm/s) 6.8 (5.3-7.9) 6.1 (5.3-7.6) 5.8 (4.8-6.5) 5.7 (4.1-6.2) 0.002*
E' lateral (cm/s) 9.9 (8.2-10.9) 8.2 (6.9-10.5) 7.6 (7.0-8.6) 7.3 (5.6-8.8) <0.001*
Average E' 8.3 (7.0-9.6) 7.3 (6.1-8.7) 6.8 (6.0-7.7) 6.3 (5.0-7.3) <0.001*
E/E' septal ratio 8.8 (8.0-11.4) 10.5 (8.5-12.7) 11.4 (8.3-14.1) 14.5 (11.5-17.1) <0.001*
E/E' average ratio 7.4 (6.7-9.3) 9.0 (7.4-10.5) 9.4 (7.5-11.3) 12.1 (10.1-15.4) <0.001*
Laboratory
NT-pro BNP (pg/ml) 98 (64-189) 120 (90-253) 183 (65-502) 406 (117-773) <0.001*
* Statistically significant (p < 0.05). aJonckheere-Terpstra test. A - late diastolic transmitral inflow velocity, EF - ejection fraction. GLS - global longitudinal strain, LA - left 
atrial, E - early diastolic transmitral inflow velocity, E´septal - early diastolic tissue Doppler velocity septal, E´ lateral - early diastolic tissue Doppler velocity lateral, LV - left 
ventricular, LVEDD - left ventricular end diastolic diameter, LVM - left ventricular muscle mass index, NT-pro BNP - amino-terminal pro-B-type natriuretic peptide, RWT - 
relative wall thickness. Smax - systolic velocity. The growth differentiation factor-15 (GDF-15) levels in the first quartile ranged from 0.37 - 0.93ng/ml, in the second quartile 
from 0.93 - 1.28 ng/ml, in the third quartile from 1.28 - 2.02 ng/ml and in the fourth quartile from 2.02 - 3.60 ng/ml (p = 0.005 in the Jonckheere-Terpstra-Test).
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Figure 3a - Change in cardiac output response from upright to supine position. The y-axis shows the change in the cardiac output index by changes in body position 
from upright to supine measured by inert gas rebreathing techniques. Cardiac output index is presented as box (25th percentile, median, 75th percentile), and whiskers 






















Figure 3b - Change in cardiac output response from upright to supine position stratified according to growth differentiation factor-15 quartiles. The y-axis shows the 
change in the cardiac output index caused by changes in body position from upright to supine measured non-invasively by inert gas rebreathing techniques. Cardiac 
output index is presented as box (25th percentile, median, 75th percentile), and whiskers plots, upper outliers are presented as black dots. The growth differentiation 
factor-15 (GDF-15) levels in the first quartile ranged from 0.33 - 0.83ng/ml, in the second quartile from 0.83 - 1.13 ng/ml, in the third quartile from 1.13 - 1.54 ng/ml and 
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symptomatic status of patients with heart failure31. Consistent 
with the fact that GDF-15 expression is activated in response 
to stress27, our data showed a significant negative correlation 
between the magnitude of COi response to the changes in 
body position from upright to supine, which can be considered 
a model of preload change. The association of a reduced 
cardiac output response to preload stress and increased GDF-
15 levels confirmed the hypothesis that the adaptive response 
of GDF-expression is countermanded by the severity of the 
underlying disease. This is further reinforced particularly by the 
correlation of GDF-15 and the LAi, a parameter that indicates 
severe diastolic function abnormalities over a longer period 
of time. An increased LAi without concomitant mitral valve 
disease reflects an enduring cumulative effect of different 
contributors to the development of LVDD and is therefore 
less vulnerable to intermittent changes in preload (e.g. volume 
status) or afterload (e.g. blood pressure). Acute changes in 
these conditions during echocardiographic diagnosis might 
lead to misclassifications of diastolic function abnormalities.
The finding of an association between GDF-15 and LVDD is 
in line with a recent study of Stahrenberg et al32 that assessed 
the relationship in a community based trial. Nevertheless, 
there are some concerns about methodological issues that 
might have influenced the results presented in this interesting 
study. Most important, there was no general screening for 
the presence of CAD with either noninvasive stress testing 
or coronary angiography. Since CAD has been shown to be 
associated both with elevated GDF-15 levels28,33 and LVDD34, 
the lack of information on coronary morphology is a potential 
source of bias towards increased plasma levels of GDF-15 and 
toward an increased prevalence and/or severity of LVDD. 
In accordance with the uncertainties about the presence of 
CAD, the E/E’ ratio was not averaged based on medial and 
lateral velocities, as recommended by the current guidelines10. 
Because some of the patients likely had regional wall motion 
abnormalities, tethering effects might have been a possible 
source of bias. Moreover, patients were not screened with 
an oral glucose tolerance test for undetected diabetes, which 
have been associated both with increased GDF-15 levels35,36 
and the presence and severity of LVDD, especially in subjects 
with newly detected diabetes on oGTT37. 
In contrast, the present study followed the current 
guidelines for the diagnosis of LVDD in subjects well 
characterized for the degree of abnormality in plasma glucose 
levels and coronary morphology. Therefore, we were able to 
reinforce the data of Stahrenberg et al32. in a different cohort 
of patients with known coronary morphology and metabolic 
status. Furthermore, we extended the findings to a functional 
hemodynamic parameter, as we were able to demonstrate 
an association of GDF-15 levels with an impairment of the 
hemodynamic response to different preload conditions.
Limitations
The number of patients, especially with normal DF in our 
cohort, was relatively small, resulting in a limited statistical 
power. Furthermore, the rates of CAD and cardiovascular 
risk factors were high in this study population. Therefore, 
the present results may not readily represent the general 
population. In addition, patients with HFnEF were older than 
those with normal diastolic function, a potential source of bias 
towards increased plasma levels of GDF-15. Nevertheless, 
association between LVDD and GDF-15 remains significant 
after adjustment for CAD, age, glucose metabolism and 
hypertension as covariates into multivariate regression 
models. Although we based the diagnosis of LVDD on current 
guidelines which have recently been published, their clinical 
value has yet to be prospectively validated. Furthermore, the 
rate of patients on antihypertensive treatment was higher in 
the HFnEF group. Nevertheless, a significant relation of any of 
these drugs to the increased GDF-15 plasma levels has never 
been identified. Lastly, our cross sectional study design does 
not permit any conclusions on causality.
Conclusion
GDF-15 is a novel promising biomarker in HFnEF that is 
elevated in subjects with either mild or moderate to severe 
LVDD regardless of the presence of CAD or other established 
risk factors frequently associated with HFnNF. Considering the 
fact that GDF-15 appears to have cardioprotective functions, 
we hypothesize that higher levels of GDF-15 may reflect 
an adaptive response that is outweighed by the severity of 
the underlying disease. Incorporating a biomarker to aid in 
diagnosis, and risk prediction in HFnEF may enhance the 
ability to accurately and early identify patients at greatest risk 
for heart failure-related complications. Better characterization 
of patients with HFnEF could allow a more effective use of 
specific therapeutic and prevention strategies. Further studies 
are needed to determine the value of GDF-15 for diagnosis 
and therapy monitoring in diastolic heart failure.
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